Your browser doesn't support javascript.
loading
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.
Kiani, Zahra; Khorsand, Nadereh; Beigi, Fahimeh; Askari, Gholamreza; Sharma, Manoj; Bagherniya, Mohammad.
Afiliação
  • Kiani Z; Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Khorsand N; Department of Internal Medicine, Imam Musa Kazem Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Beigi F; Pharmaceutical Biotechnology Department, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Science, Isfahan, Iran.
  • Askari G; Research and Development Unit, Imam Muss Kazim Hospital, Isfahan University of Medical Science, Isfahan, Iran.
  • Sharma M; Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Bagherniya M; Anesthesia and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Trials ; 25(1): 160, 2024 Mar 02.
Article em En | MEDLINE | ID: mdl-38431600
ABSTRACT

BACKGROUND:

Burn injuries are important medical problems that, aside from skin damage, cause a systemic response including inflammation, oxidative stress, endocrine disorders, immune response, and hypermetabolic and catabolic responses which affect all the organs in the body. The aim of this study was to determine the effect of coenzyme Q10 (CoQ10) supplementation on inflammation, oxidative stress, and clinical outcomes in burn patients.

METHODS:

In a double-blind placebo-controlled randomized clinical trial, 60 burn patients were randomly assigned to receive 100 mg CoQ10 three times a day (total 300 mg/day) or a placebo for 10 days. Inflammatory markers including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), oxidative stress markers including total antioxidant capacity (TAC), malondialdehyde (MDA) and superoxide dismutase (SOD) activity, fasting blood glucose (FBG), blood urea nitrogen (BUN), creatinine, white blood cells (WBC), and body temperature were assessed as primary outcomes and albumin, prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR), other hematological parameters, blood pressure, O2 saturation, ICU duration, and 28-mortality rate were assessed as secondary outcomes.

RESULTS:

Fifty-two participants completed the trial. CRP and ESR levels were not significantly different between CoQ10 and placebo groups at the end of the study (P = 0.550 and P = 0.306, respectively). No significant differences between groups were observed for TAC (P = 0.865), MDA (P = 0.692), and SOD activity (P = 0.633) as well. Administration of CoQ10 resulted in a significant increase in albumin levels compared to placebo (P = 0.031). There was no statistically significant difference between the two groups in other measured outcomes (P > 0.05).

CONCLUSION:

Results showed that in patients with burn injury, CoQ10 administration had no effect on inflammatory markers and oxidative stress, although serum albumin levels were improved after supplementation. Further studies with albumin as the primary outcome are needed to confirm this finding.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ubiquinona / Suplementos Nutricionais / Antioxidantes Idioma: En Revista: Trials Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ubiquinona / Suplementos Nutricionais / Antioxidantes Idioma: En Revista: Trials Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Irã